SCHEMBL5665083

SCHEMBL5665083

O=C(NC1CC1)c1ccc(C2CC3C=C(c4c[nH]c(-c5ccc(F)cc5)c4-c4ccncc4)CCN3C2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK11 Q15759 1/20 0.58
MAPK14 Q16539 1/20 0.58
USP30 Q70CQ3 2/20 0.37
CYP46A1 Q9Y6A2 1/20 0.37
HPGD P15428 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
DRD2 P14416 1/20 0.34
DRD4 P21917 1/20 0.34
IGF1R P08069 1/20 0.34
CDK2 P24941 1/20 0.34
DYRK1B Q9Y463 1/20 0.34
CTSB P07858 1/20 0.34
CTSS P25774 1/20 0.34
CTSK P43235 1/20 0.34
CTSC P53634 1/20 0.34
KMT2A Q03164 1/20 0.34
F2R P25116 1/20 0.34
MAPT P10636 1/20 0.33
ROCK2 O75116 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5650805 1.00 MAPK11 (0.58) MAPK11MAPK14USP30CYP46A1HPGD
SCHEMBL5751855 0.91 MAPK11 (0.58) MAPK11MAPK14ALOX5
SCHEMBL5650802 0.91 MAPK11 (0.58) MAPK11MAPK14ALOX5
SCHEMBL5667190 0.90 MAPK14 (0.55) MAPK11MAPK14ALOX5
SCHEMBL5652029 0.90 MAPK14 (0.55) MAPK11MAPK14ALOX5
SCHEMBL5646091 0.89 MAPK14 (0.56) MAPK11MAPK14ALOX5
SCHEMBL5651405 0.89 MAPK14 (0.61) MAPK11MAPK14ALOX5
SCHEMBL5650860 0.89 MAPK14 (0.54) MAPK11MAPK14DRD4
SCHEMBL5665333 0.89 MAPK14 (0.54) MAPK11MAPK14DRD4
SCHEMBL5651554 0.89 MAPK14 (0.55) MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1632488-A1 CYCLIC TERTIARY AMINE COMPOUND Sankyo Company, Limited (JP) 2006-03-08 EP claimed
US-20070049620-A1 Cyclic tertiary amine compound SANKYO COMPANY, LIMITED (JP) 2007-03-01 US disclosed
EP-1632488-A1 CYCLIC TERTIARY AMINE COMPOUND Sankyo Company, Limited (JP) 2006-03-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049620-A1 Cyclic tertiary amine compound MYD88, IL5, BRD4 MAPK11 520/4885MAPK14 467/4885USP30 2815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.